A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect

• Main Authors: Jonas Hannestad (Author), Steven Smith (Author), Andrew Lam (Author), Janet Hurt (Author), Nicole Harada (Author), Richard Kim (Author), Abhirup Das (Author), Juliana Brunello (Author), Gareth Whitaker (Author), David Chalmers (Author), Faria Senjoti (Author), Wu Lin (Author), James Coghill (Author), Yogesh Bansal (Author), Sharan Sidhu (Author), Vanessa Zann (Author), Enchi Liu (Author)
• Format: Book
• Published: Wiley, 2024-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract TQS‐168, a first‐in‐class small‐molecule inducer of peroxisome proliferator‐activated receptor gamma coactivator 1‐alpha gene expression, is in development for the treatment of amyotrophic lateral sclerosis. A single‐ascending‐dose (SAD) and multiple‐ascending‐dose (MAD) study of TQS‐168 wa...